"Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes"

Lu, Qin; Eggimann, Philippe; Luyt, Charles-Edouard; Wolff, Michel; Tamm, Michael; François, Bruno; Mercier, Emmanuelle; Garbino, Jorge; Laterre, Pierre-François; Koch, Holger; Gafner, Verena; Rudolf, Michael P; Mus, Erkan; Perez, Antonio; Lazar, Hedvika; Chastre, Jean; Rouby, Jean-Jacques

ABSTRACT

INTRODUCTION: Pseudomonas aeruginosa frequently causes nosocomial pneumonia and is associated with poor outcome. The purpose of this study was to assess the prevalence and clinical outcome of nosocomial pneumonia caused by serotype-specific P. aeruginosa in critically ill patients under appropriate antimicrobial therapy management. METHODS: A retrospective, non-interventional epidemiological multicenter cohort study involving 143 patients with confirmed nosocomial pneumonia caused by P. aeruginosa. Patients were analyzed for a period of 30 days from time of nosocomial pneumonia onset. Fourteen patients fulfilling the same criteria from a phase IIa study conducted at the same time/centers were included in the prevalence calculations but not in the clinical outcome analysis. RESULTS: The prevalence of serotypes was: O6 (29%), O11 (23%), O10 (10%), O2 (9%), and O1 (8%). Serotypes with a prevalence of less than 5% were found in 13% of patients, 8% were classified as not typeable. Across all serotypes, 19% mortality, 70% clinical resolution, 11% clinical continuation, and 5% clinical recurrence were recorded. Age and higher APACHE II (Acute Physiology and Chronic Health Evaluation II) were predictive risk factors associated with probability of death and lower clinical resolution for P. aeruginosa nosocomial pneumonia. Mortality tends to be higher with O1 (40%) and lower with O2 (0%); clinical resolution tends to be better with O2 (82%) compared to other serotypes. Persisting pneumonia with O6 and O11 was, respectively, 8% and 21%; clinical resolution with O6 and O11 was, respec...

CITE THIS VERSION

Lu, Qin; Eggimann, Philippe; Luyt, Charles-Edouard; Wolff, Michel; Tamm, Michael; et. al. Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes. In: Critical Care, Vol. 18, no.1, p. R17 [1-9] (2014) http://hdl.handle.net/2078.1/171716 -- DOI : 10.1186/cc13697

Le dépôt institutionnel DIAL est destiné au dépôt et à la diffusion de documents scientifiques émanant des membres de l'UCLouvain. Toute utilisation de ce document à des fins lucratives ou commerciales est strictement interdite. L'utilisateur s'engage à respecter les droits d'auteur liés à ce document, principalement le droit à l'intégrité de l'œuvre et le droit à la paternité. La politique complète de copyright est disponible sur la page Copyright policy.

DIAL is an institutional repository for the deposit and dissemination of scientific documents from UCLouvain members. Usage of this document for profit or commercial purposes is strictly prohibited. User agrees to respect copyright about this document, mainly text integrity and source mention. Full content of copyright policy is available at Copyright policy.

Available at: http://hdl.handle.net/2078.1/171716
Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes

Qin Lu, Philippe Eggimann, Charles-Edouard Luyt, Michel Wolff, Michael Tamm, Bruno François, Emmanuelle Mercier, Jorge Garbino, Pierre-François Laterre, Holger Koch, Verena Gafner, Michael P Rudolf, Erkan Mus, Antonio Perez, Hedvika Lazar, Jean Chastre and Jean-Jacques Rouby

Abstract

Introduction: Pseudomonas aeruginosa frequently causes nosocomial pneumonia and is associated with poor outcome. The purpose of this study was to assess the prevalence and clinical outcome of nosocomial pneumonia caused by serotype-specific P. aeruginosa in critically ill patients under appropriate antimicrobial therapy management.

Methods: A retrospective, non-interventional epidemiological multicenter cohort study involving 143 patients with confirmed nosocomial pneumonia caused by P. aeruginosa. Patients were analyzed for a period of 30 days from time of nosocomial pneumonia onset. Fourteen patients fulfilling the same criteria from a phase IIa study conducted at the same time/centers were included in the prevalence calculations but not in the clinical outcome analysis.

Results: The prevalence of serotypes was: O6 (29%), O11 (23%), O10 (10%), O2 (9%), and O1 (8%). Serotypes with a prevalence of less than 5% were found in 13% of patients, 8% were classified as not typeable. Across all serotypes, 19% mortality, 70% clinical resolution, 11% clinical continuation, and 5% clinical recurrence were recorded. Age and higher APACHE II (Acute Physiology and Chronic Health Evaluation II) were predictive risk factors associated with probability of death and lower clinical resolution for P. aeruginosa nosocomial pneumonia. Mortality tends to be higher with O1 (40%) and lower with O2 (0%); clinical resolution tends to be better with O2 (82%) compared to other serotypes. Persisting pneumonia with O6 and O11 was, respectively, 8% and 21%; clinical resolution with O6 and O11 was, respectively, 75% and 57%.

Conclusions: In P. aeruginosa nosocomial pneumonia, the most prevalent serotypes were O6 and O11. Further studies including larger group sizes are needed to correlate clinical outcome with virulence factors of P. aeruginosa in patients with nosocomial pneumonia caused by various serotypes; and to compare O6 and O11, the two serotypes most frequently encountered in critically ill patients.
Strains exhibiting exotoxin U (ExoU), one of the toxins secreted by the type III secretion system (TTSS), were frequently serotyped as O11, whereas serotype O6 strains were associated with a negative ExoU phenotype [12,15]. In an experimental model of pneumonia, serotype O11 was found to be associated with increased lung injury [15]. Moreover, it has been reported that some serotypes are able to induce high resistance of *P. aeruginosa* to antibiotics [16-18].

Little is known, however, about the prevalence of *P. aeruginosa* serotypes in nosocomial pneumonia and the correlation between serotypes and clinical outcome. The primary objective of the study was to assess the prevalence of *P. aeruginosa* serotypes in critically ill patients with nosocomial pneumonia. The secondary objective was to report clinical outcome of nosocomial pneumonia caused by different serotypes of *P. aeruginosa*.

**Materials and methods**

**Study design and patients**

This was a retrospective, multicenter, and non-interventional epidemiological cohort study conducted between 2007 and 2009 in the ICU of nine hospitals in France, Switzerland, and Belgium. Patients with confirmed hospital-acquired pneumonia (HAP) and VAP caused by *P. aeruginosa* were analyzed for a period of 30 days from the time of diagnosis of pneumonia. The following ethics committees approved the study: Basel Ethikkommission beider Basel EKBB, Geneva Commission d'Éthique du Département de Médecine, Hôpitaux Universitaires de Gèneve, Lausanne Commission d'Éthique de la Recherche Clinique de la Faculté de Biologie et Médecine, le Comité de Protection des Personnes, Ile de France-VI, Brussels Université Catholique de Louvain, Faculté de Médecine, Commission d’Éthique Biomédecale Hospitale-Facultaire. Because it was a retrospective epidemiological study, no informed consent was needed. Written informed consent was obtained in only 14 patients with serotype O11 HAP or VAP when they were included in a phase IIa study [19].

**Inclusion criteria**

Included patients were at least 18 years old, required intensive care management with HAP and VAP, were expected to survive longer than 72 hours, and fulfilled one of the following two criteria [20]:

1. Confirmed microbiological diagnosis of HAP and VAP caused by *P. aeruginosa* isolated from lower respiratory tract specimen with significant threshold of at least $1 \times 10^4$ colony-forming units (CFU)/mL for bronchoalveolar lavage (BAL) [21] or $1 \times 10^3$ CFU/mL for protected mini-lavage (mini-BAL) [22], or below if under treatment with antibiotics, and presence of a new or progressing pulmonary infiltrate, plus one of the following three criteria: (a) fever of greater than 38°C, (b) white blood cell count of greater than 10,000/mm$^3$, or (c) purulent sputum

2. Confirmed microbiological diagnosis of HAP and VAP caused by *P. aeruginosa* isolated from endotracheal aspirate (ETA) with at least $1 \times 10^6$ CFU/mL and a modified clinical pulmonary infection score (MCPI) of higher than 6 points [23].

Patients with nosocomial pneumonia caused by multiple bacteria were included in the study. Multiple bacteria were defined as more than one pathogen reaching significant threshold isolated from lower respiratory tract specimen.

**Exclusion criteria**

During the same period of time and at the same centers, a phase IIa study which included 14 patients with O11 HAP or VAP was performed [19]. To reflect the correct prevalence of O11 serotype during the observation period, these patients were included in the prevalence calculation. They were, however, excluded from the clinical outcome analysis as they were treated with a combination of standard antibiotic treatment plus an adjunctive immunotherapy [19]. Exclusion criteria were applicable to only the 14 patients who participated in the phase IIa study. They included use of any investigational drug within 30 days prior to study commencement or during the study; patients with a known complement deficiency associated with systemic lupus erythematosus, paroxysmal nocturnal hemoglobinuria, hereditary angioedema, membranoproliferative glomerulonephritis, collagen vascular disease, autoimmune hepatitis, primary biliary cirrhosis, scleroderma, or recurrent *Neisseria* infections; or patients with confirmed HIV infection. Transplant patients and/or patients treated with systemic immuno-suppressive drugs (except prednisone or prednisolone), patients with a known liver function deficiency, and neutropenic patients (absolute neutrophil count of less than 1,000 cells/μL) were also excluded [19].

**Assessments**

Serotypes of *P. aeruginosa* isolated from lower respiratory tract specimens were determined by agglutination using serotype-specific antisera (Bio-Rad, Marnes-la Coquette, France) in accordance with the instructions of the manufacturer.

Patient clinical characteristics, Acute Physiology and Chronic Health Evaluation II (APACHE II) score [24], sequential organ failure assessment (SOFA) score, MCPIS, risk factors, microbiological assessments (including serotyping) in ETA or BAL/mini-BAL, blood culture, chest radiographies,
and laboratory parameters were assessed at inclusion. Scores, laboratory parameters, chest radiographies, and body temperature were collected as frequently as possible from day 1 to day 15, at days 21 and 30, or end of study (EOS) until patient died or was lost for follow-up.

Data collected at day 30 or EOS, whichever date was earlier, included clinical outcome, scores, laboratory parameters, chest radiographies, body temperature, discharge from the ICU, and discharge from the hospital. Clinical outcome was defined as follows:

- Continuation: clinical signs and symptoms of pneumonia present during the whole assessment period until day 30 (or EOS)
- Resolution: complete resolution of pneumonia signs and symptoms present at the time of enrollment, no new symptoms or complications attributable to the pneumonia, no recurrence of pneumonia, and alive, until day 30 (or EOS)
- Recurrence: return of all clinical signs and symptoms of HAP/VAP, including infiltrates after initial clinical resolution
- Death: assessment period until day 30 (or EOS). Actual mortality was compared with predicted mortality according to APACHE II score [24].

Microbiological outcome was defined as follows:

- Continuation: positive culture of *P. aeruginosa* in ETA or (mini)-BAL over the whole assessment period until day 30 (or EOS) associated with persisting clinical signs and symptoms of pneumonia
- Resolution: baseline isolate not present in repeated culture from original infection site
- Recurrence: isolation of *P. aeruginosa* from a culture taken after the resolution of pneumonia
- Colonization: positive culture of *P. aeruginosa* in ETA or (mini)-BAL over the whole assessment period until day 30 (or EOS) without any clinical pneumonia signs and symptoms.

**Statistical analysis**

Descriptive statistics were used for patient characteristics and outcome variables. Categorical variables were expressed as percentage, and continuous variables as mean ± standard deviation or as median and 25% to 75% interquartile range according to data distribution. Clinical and microbiological outcomes were considered binary endpoints and these were analyzed by using Bayesian logistic regression models. Logistic regression was used for binary outcomes and model based *P* values, using likelihood ratio tests. Time-to-event endpoints (survival and clinical and microbiological resolution) were analyzed by using Kaplan-Meier and Cox proportional hazards regression models. Analysis was done without adjustment for risk factors, with adjustment for different serotypes, and with adjustment for risk factors (age, APACHE II score, CPIS, SOFA score, and adequacy of antibiotic treatment). Analyses of data were performed by using R 2.10.1 and WinBUGS 1.4.3.

**Results**

**Patient demographics and characteristics**

Patients’ flow chart is shown in Figure 1. Of 143 patients, 123 patients were included in the prevalence analysis and 129 in the overall clinical outcome analysis. Among 123 patients with serotype available, 114 patients had VAP (93%) and 9 had HAP (7%). Clinical and demographic data are shown in Table 1. At pneumonia onset, median length of hospital stay was 13 days, median length of ICU stay was 8 days, and median duration of mechanical ventilation was 8 days.

**Prevalence of *Pseudomonas aeruginosa* serotypes**

The rates of prevalence of serotypes were, respectively, O6 (29%), O11 (23%), O10 (10%), O2 (9%), and O1 (8%). The sum of all serotypes with a prevalence of less than 5% (PL5) was 13%, and 8% of all patients had a *P. aeruginosa* infection classified as not typeable (NT) (Table 2). The prevalence of *P. aeruginosa* serotypes in French and Swiss investigator centers is shown in Figure 2. The distribution of *P. aeruginosa* serotypes by each investigator site is shown in Table 3.

**Overall clinical outcome**

On day 30, across all serotypes, a 19% mortality, a 70% clinical resolution, an 11% clinical continuation, and a 5% clinical recurrence were recorded. Mortality was associated with age (*P* = 0.012) and high APACHE II score (*P* = 0.003). Clinical resolution was not associated with any of the risk factors—APACHE II score, CPIS score, SOFA score, adequate antibiotic treatment and age—or interaction of risk factors. Clinical continuation was associated with high APACHE II score (*P* <0.001).

Time to death was associated with age (*P* = 0.015) and high APACHE II score (*P* = 0.010). Time to event analysis of clinical resolution was associated with high APACHE II score (*P* = 0.008).

Among 102 patients with microbiological information available, a 41% microbiological resolution, a 25% microbiological continuation, a 23% colonization, and an 11% microbiological recurrence were recorded. Time to microbiological resolution was associated with APACHE II score (*P* <0.001) and higher MCPIS (*P* <0.007).

**Clinical outcome according to *Pseudomonas aeruginosa* serotype**

Among 109 patients (Figure 1), 15% of patients had nosocomial pneumonia caused by multiple bacteria,
which were evenly distributed among the different serotype groups. An 18% mortality and a 69% clinical resolution were recorded. The highest mortality rate was observed in patients with serotype O1 infections (40%), and the lowest in patients with serotype O2 infections (0%) (Figure 3). Actual mortality and predicted mortality by APACHE II score were similar in patients infected by serotypes O1, O10, and O11, whereas actual mortality was lower than predicted mortality in patients infected by serotypes PL5, O6, NT, and O2 (Figure 3).

As shown in Figure 4, the highest clinical resolution rate was found in patients with serotype O2 (82%) and the lowest in patients with serotype O1 (40%). The serotypes O1, O10, O11, and NT had lower rates of clinical resolution (40%, 58%, 57%, and 60%) and higher rates of continuation (20%, 17%, 21%, and 30%), whereas the serotypes O6 and the PL5 group had continuation rates below 10%. The highest rates of recurrence were found in patients with serotype O1, whereas none of the 11 patients with serotype O10 and PL5 relapsed.

Table 1 Clinical characteristics of patients with nosocomial pneumonia caused by different Pseudomonas aeruginosa serotypes (n = 123)

| Serotypes | All | O1 | O2 | O6 | O10 | O11 | PL5 | NT |
|-----------|-----|----|----|----|-----|-----|-----|----|
| VAP/NP, n (%) | 114/123 (93) | 9/10 (90) | 10/11 (91) | 35/36 (92) | 10/12 (83) | 26/28 (93) | 15/16 (94) | 9/10 (90) |
| Age, years | 61 (43 to 72) | 65 (56 to 74) | 63 (58 to 70) | 57 (39 to 67) | 59 (40 to 77) | 65 (42 to 78) | 64 (47 to 71) | 64 (59 to 72) |
| Male% | 75 | 40 | 73 | 81 | 92 | 68 | 81 | 80 |
| Antibiotics at pneumonia onset, n (%) | 84 (68) | 5 (50) | 8 (73) | 28 (78) | 12 (100) | 13 (46) | 12 (75) | 6 (60) |
| Inappropriately treated % | 11 | 0 | 0 | 14 | 8 | 14 | 6 | 0 |
| MCPIS | 7.0 (5.0 to 9.0) | 8.0 (5.8 to 9.5) | 9.0 (7 to 10) | 7 (5 to 8) | 6 (4 to 8) | 8.5 (7 to 9.5) | 7.5 (5 to 9) | 6.0 (4 to 8) |
| APACHE II score | 17 (12 to 22) | 17 (11 to 29) | 15 (11 to 17) | 17 (11 to 23) | 17 (11 to 29) | 17 (14 to 20) | 19 (12 to 26) | 16 (12 to 19) |
| SOFA score | 7.0 (5.0 to 10.0) | 9.5 (6.5 to 15.0) | 5 (4 to 7) | 7 (5 to 10) | 9.5 (6.5 to 15.0) | 6.0 (4.5 to 8.0) | 7 (6.0 to 9.0) | 6.0 (4.0 to 9.2) |
| Hospital length of stay at inclusion, days | 13 (7 to 14) | 14 (8 to 45) | 8 (4 to 18) | 12 (7 to 25) | 13 (8 to 19) | 18 (8 to 34) | 12 (6 to 24) | 14 (8 to 25) |
| ICU length of stay at inclusion, days | 8 (4 to 17) | 11 (4 to 17) | 5 (3 to 12) | 7 (5 to 19) | 8 (3 to 13) | 9 (6 to 19) | 8 (4 to 15) | 9 (5 to 14) |
| Duration of mechanical ventilation at inclusion, days | 8 (5 to 17) | 10.5 (7 to 17) | 5 (3 to 12) | 8 (5 to 18) | 9 (4 to 13) | 9 (5 to 17) | 8 (4 to 15) | 9 (6 to 14) |

Data are expressed as median and 25%-75% interquartile. Nosocomial pneumonia (NP) includes hospital-acquired pneumonia and ventilator-associated pneumonia (VAP). APACHE II, Acute Physiology and Chronic Health Evaluation II; ICU, intensive care unit; MCPIS, modified clinical pulmonary infection score; NT, not typeable; PL5, sum of all serotypes with a prevalence of less than 5%; SOFA, sequential organ failure assessment.
Mean time to death across all groups with nosocomial pneumonia was 11.4 days (Table 4). Overall time to resolution was 12.1 days, the shortest being for the patients with O2 infections (10 days) and longest being for the patients with O11 infections (13.4 days) (Table 4).

Discussion
Our study shows that, of the 20 different serotypes of \textit{P. aeruginosa}, O6 (29%) and O11 (23%) were the most prevalent serotypes, responsible for the majority of nosocomial pneumonia. Across all serotypes, clinical outcome correlates strongly to APACHE score. Mortality and clinical resolution tend to be worse in patients infected by \textit{P. aeruginosa} serotype O1 and better in patients infected by serotypes O2 and NT and O6.

**Prevalence of \textit{Pseudomonas aeruginosa} serotypes**
While the prevalence of \textit{P. aeruginosa} serotype varies from one hospital to another and from one country to another, O6 and O11 are often the most prevalent serotypes reported in previous studies [10,14,25-30]. It should be pointed out that the prevalence of \textit{P. aeruginosa} serotypes reported in previous studies was obtained either from multiple infectious sites or from a single hospital or country. To the best of our knowledge, our study is the first assessing the prevalence of \textit{P. aeruginosa} serotypes in nosocomial pneumonia from different hospitals of different countries.

Although the prevalence of serotypes is different among the countries and investigator sites (Figure 2 and Table 3), the overall rates of prevalence of the most common \textit{P. aeruginosa} serotypes observed in patients with nosocomial pneumonia were O6 and O11. After exclusion of the largest enrollment site from the analysis, O6 and O11 remain the most prevalent serotypes, suggesting that investigator site effect does not influence interpretation of the finding. This result is comparable with those previously reported in the literature [10,15,25,26,28]. In approximately 8% of cases, the standard method failed to detect serotype because of self-agglutinating or non-agglutinating strains and the samples were classified as “not typeable”. This proportion is less than those previously reported [11,18,27].

**Clinical outcome and \textit{Pseudomonas aeruginosa} serotypes**
Age and APACHE II score were found to be the predictive risk factors for nosocomial pneumonia caused by \textit{P. aeruginosa}. This result indicates that mortality and clinical and microbiological resolutions were strongly correlated with severity of the patients at the initial phase of pneumonia [31-33].

The relationship between virulence of \textit{P. aeruginosa} and different serotypes has been investigated in a few studies [12-14]. It has been shown that clinical strains lacking B-band O antigen increase TTSS and virulence [34]. On the other hand, it was found that strains secreting ExoU were frequently serotyped as O11 [12,15]. ExoU is one of the toxins secreted by TTSS and contributes to epithelial cell toxicity, lung injury, and sepsis in infected animals [35,36]. Exo S and Exo T disrupt the host cell actin cytoskeleton, block phagocytosis, and are associated with mortality in animal models [37]. Furthermore, TTSS is associated with persistent VAP caused by \textit{P. aeruginosa} and poor clinical outcome [38,39]. Faure et al. reported that, among 13 \textit{P. aeruginosa} O1 strains, 7 secreted Exo S [12]. Recently, Le Berre et al. showed that the O11 serotype, elastase production, and TTSS were associated with increased lung injury in a murine model.
They found that serotype O11 strains were significantly more virulent than non-typeable strains and serotype O6; O11 strains were associated with a positive (ExoU) phenotype, whereas O6 strains were associated with negative ExoU phenotype [12,15]. These results suggest that clinical outcome of patients with pneumonia caused by P. aeruginosa could be related to serotypes.

This article reports on the first ever study to assess the clinical outcome of nosocomial pneumonia caused by a range of different serotypes of P. aeruginosa in critically ill patients under standard ICU management. Interestingly, the results show that the mortality rates for serotypes O1, O10, and O11 were in line with the expected mortality rates estimated by the severity of the patients (APACHE II score). Infections with serotypes O6, O2, and NT serotypes, however, had lower mortality than expected. There was a trend toward poorer outcome of patients with pneumonia caused by serotypes O1.

**Table 3** Pseudomonas aeruginosa serotype distribution by each investigator site

| Investigator site | O1  | O2  | O6  | O10 | O11 | PL5 | NT | Total |
|------------------|-----|-----|-----|-----|-----|-----|----|-------|
| 1                | n   | 2   | 0   | 8   | 2   | 1   | 2  | 16    |
|                  | %   | 12.5% | 0.0% | 50.0% | 12.5% | 6.3% | 12.5% | 6.3% | 100% |
| 2                | n   | 1   | 0   | 3   | 2   | 2   | 2  | 13    |
|                  | %   | 7.7% | 0.0% | 23.1% | 15.4% | 15.4% | 23.1% | 15.4% | 100% |
| 3                | n   | 2   | 4   | 12  | 1   | 14  | 4  | 40    |
|                  | %   | 5.0% | 10.0% | 30.0% | 2.5% | 35.0% | 10.0% | 7.5% | 100% |
| 4                | n   | 0   | 0   | 3   | 1   | 3   | 1  | 10    |
|                  | %   | 0.0% | 0.0% | 30.0% | 10.0% | 30.0% | 10.0% | 20.0% | 100% |
| 5                | n   | 1   | 1   | 5   | 0   | 1   | 2  | 10    |
|                  | %   | 10.0% | 10.0% | 50.0% | 0.0% | 10.0% | 20.0% | 0.0% | 100% |
| 6                | n   | 4   | 5   | 4   | 1   | 2   | 2  | 18    |
|                  | %   | 22.2% | 27.8% | 22.2% | 5.6% | 11.1% | 11.1% | 0.0% | 100% |
| 7                | n   | 0   | 1   | 1   | 5   | 1   | 2  | 12    |
|                  | %   | 0.0% | 8.3% | 8.3% | 41.7% | 8.3% | 16.7% | 16.7% | 100% |

Investigator sites with more than 10 patients were analyzed. Percentages of serotype are expressed in boldface. NT, not typeable; PL5, sum of all serotypes with a prevalence of less than 5%.

**Figure 3** Percentages of predicted and actual mortality of patients with nosocomial pneumonia caused by different Pseudomonas aeruginosa serotypes. Black bars indicate actual mortality, and white bars indicate predicted mortality estimated according to Acute Physiology and Chronic Health Evaluation II (APACHE II) score. NT, not typeable; PL5, sum of all serotypes with a prevalence of less than 5%.

**Figure 4** Proportions of death (black bars), persisting pneumonia (or continuation) (red bars), and clinical resolution (green bars) of patients with nosocomial pneumonia caused by different Pseudomonas aeruginosa serotypes. NT, not typeable; PL5, sum of all serotypes with a prevalence of less than 5%.
By cross-referencing prevalence and mortality rates, one can see that, while the O6 serotype is the most prevalent (29%), it has lower levels of continuation (8%) and death (17%) and higher resolution rates (75%) than the second most prevalent serotype O11 (prevalence 23%, continuation 21%, death rate 21%, and resolution 57%). This finding could be explained by the absence of ExoU with serotype O6 and presence of ExoU with serotype O11 as previously reported [15]. Consequently, compared with O6, O11 may be a more clinically relevant target for therapy in terms of patient outcomes [19]. Further study with larger groups is required in order to draw firm conclusions.

**Methodological limitations**

First, the prevalence obtained from our study may not be applied globally, because of an absence of data from additional countries known for their high prevalence of pneumonia caused by *P. aeruginosa*, such as Spain, Italy, Greece, the US, Mexico, Canada, and Japan. Serotypes may also vary from hospital to hospital within a given country and within the same hospital when assessed at different times. The most prevalent serotypes obtained in our study are, however, comparable to those previously reported in the literature. Second, the potential relationship between serotypes, virulence factors, and antibiotic resistance was not studied. Patients hospitalized in the same ICU could have a *P. aeruginosa* clone with the same virulence. Moreover, *P. aeruginosa* strains with the same serotype could be different clones exhibiting different virulence. Third, interpreting the results on clinical outcome is limited due to the small size of the individual serotype groups. However, these preliminary data provide relevant information for further investigations.

Further larger clinical study combining clinical outcome with distribution of virulence factors by serotypes and identification of specific clones by pulsed-field gel electrophoresis is needed to enhance the implication of these clinical findings [40].

**Conclusions**

O6 and O11 are the most prevalent serotypes in nosocomial pneumonia caused by *P. aeruginosa*. Mortality tends to be worse with O1 and better with O2; clinical resolution tends to be better with O2 and O6 compared with other serotypes, but it is difficult to draw firm conclusions given the small number of strains in each serotype group. Further large-powered multicenter study is required to assess clinical outcome of nosocomial pneumonia caused by *P. aeruginosa* serotypes, particularly O6 and O11, the two serotypes most frequently encountered in critically ill patients.

**Key messages**

- In *Pseudomonas aeruginosa* nosocomial pneumonia, the most prevalent serotypes are O6 and O11.
- Across all serotypes, mortality and clinical resolution of pneumonia correlate strongly to APACHE score.
- Clinical outcome tends to be worse with serotype O1 and better with O2, but a firm conclusion needs a larger group size.

**Table 4 Mean time to death and mean time to clinical resolution**

| Serotypes | Death/re-solution | O1 | O2 | O6 | O10 | O11 | PL5 | NT |
|-----------|------------------|----|----|----|-----|-----|-----|----|
| Time to death in days, mean ± SD | (n = 20) | (n = 4) | (n = 0) | (n = 6) | (n = 3) | (n = 5) | (n = 3) | (n = 1) |
| | 11.4 ± 7.4 | 12.0 ± 8.1 | NA | 10.2 ± 7.1 | 16.0 ± 7.2 | 12.3 ± 4.2 | 8.3 ± 4.0 | 7 |
| Time to clinical resolution in days, mean ± SD | (n = 75) | (n = 4) | (n = 10) | (n = 28) | (n = 7) | (n = 8) | (n = 12) | (n = 6) |
| | 12.1 ± 5.9 | 11.0 ± 5.8 | 9.9 ± 4.0 | 11.6 ± 6.1 | 13.1 ± 4.3 | 13.4 ± 7.2 | 13.3 ± 5.9 | 10.8 ± 4.1 |

NT: non typeable; PL5: sum of all serotypes with a prevalence of less than 5%; SD: standard deviation.

**Competing interests**

PE was involved in the Kenta Biotech (Zurich-Schlieren, Switzerland) S. aureus project KBSA301. MW has received consulting or lecture fees (or both) from Astellas (Tokyo, Japan), Gilead (Foster City, CA, USA), Pfizer (New York, NY, USA), Novartis (Basel, Switzerland), and Cubist (Lexington, MA, USA). BF has received consulting fees from Kenta Biotech, MedImmune (Gaithersburg, MD, USA), and Sanofi (Paris, France). JG has received consulting or lecture fees (or both) from Astellas, Gilead, Pfizer, Novartis, Roche (Basel, Switzerland), Merck (Whitehouse Station, NJ, USA), and Cubist. P-FL is a consultant for Kenta Biotech, Agennix (Heidelberg, Germany), and AstraZeneca (London, UK). JC has received consulting or lecture fees (or both) from Kenta Biotech, Pfizer, Brahms (Hennigsdorf, Germany), Astellas, KaloBios (South San Francisco, CA, USA), and GlaxoSmithKline (Brentford, UK). HK, HL, EMU, and MPR were employees of Kenta Biotech and owned stocks in Kenta Biotech at the time of the study. AP is external chief medical officer for Kenta Biotech and senior consultant for Aridis Pharmaceutical for Panobacumab drug development. VG is a former employee of Kenta Biotech.

**Authors’ contributions**

Investigators QL and J-JR participated in acquisition of patient data, data analysis, and drafting and reviewing of the manuscript. PE, C-EL, JC, MW, MT, BF, EMU, and P-FL participated in acquisition of patient data and reviewing of the manuscript. Kenta Biotech employees MPR and HK participated in design of the study and drafting and reviewing of the manuscript.
design of the study, data collection, data analysis, and drafting and reviewing of the manuscript. VG participated in design of the study, data collection, data analysis, and reviewing of the manuscript. All authors read and approved the final manuscript.

Acknowledgments

The design, collection, and initial analysis of the data were funded by Kenta Biotech. The final analysis and interpretation of the data, the writing of the manuscript, and the decision to submit the manuscript for publication were carried out independently by the investigators without any financial support.

Author details

1 Multidisciplinary Intensive Care Unit, Department of Anaesthesiology and Critical Care Medicine, La Pitié-Salpêtrière Hospital, Assistance Publique Hôpitaux de Paris, UPMC Paris 6, 47-83 boulevard du Hôtel, Paris 75013, France. 2 Department of Adult Intensive Care Medicine, Centre Hospitalier Universitaire Vaudois, Rue du Bugnon 46, 1011 Lausanne, Switzerland. 3 Medical Intensive Care Unit, La Pitié-Salpêtrière Hospital, Assistance Publique Hôpitaux de Paris, UPMC Paris 6, 47-83 boulevard du Hôtel, 75013 Paris, France. 4 Réanimation Médicale et Infectieuse, Hôpital Bichat-Claude Bernard, 46 Rue Henri Hurudeau, 75018 Paris, France. 5 Pneumonia Clinic, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland. 6 Intensive Care Unit, CIC-P 0801 Inserm, CHU Dupuytren, 2 avenue Martin-Luther-King, 87042 Hôpitaux de Paris, UPMC Paris 6, 47-83 boulevard de l’Europe, 75013 Paris, France. 7 Intensive Care Unit, St Luc University Hospital, UCL, Avenue Hippocrate 10, 1200 Woluwe-Saint-Lambert, Belgium. 8 Kenta Biotech, Wagistrasse 25, CH-8952 Zürich-Schlieren, Switzerland.

Received: 19 September 2013 Accepted: 8 January 2014

Published: 15 January 2014

References

1. Eggimann P, Pattie D: Infection control in the ICU. Chest 2001, 120:2059–2093.
2. Fujitani S, Sun HY, Yu VL, Weingarten JA: Relative contribution of three main somatic antigens of Pseudomonas aeruginosa - agente nosocomial pneumonia due to Pseudomonas aeruginosa: part I: epidemiology, clinical diagnosis, and source. Chest 2011, 139:909–919.
3. Crouch Brewer S, Wunderink RG, Jones CB, Leeper KV Jr: Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 1996, 109:1019–1029.
4. Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Girard C: Serotyping and serotyping of Pseudomonas aeruginosa clinical isolates. Acta Microbiol Immunol Hung 1997, 44:141–146.
5. Le Berre R, Nguyen S, Nowak E, Kipnis E, Pierre M, Quennee L, Ader F, Lancel S, Courcol R, Guerry BP, Faure K: Relative contribution of three main virulence factors in Pseudomonas aeruginosa pneumonia. Crit Care Med 2011, 39:2113–2120.
6. Pett F, Lambert-Zechovsky N: Compitative distribution of resistance patterns and serotypes in Pseudomonas aeruginosa isolates from intensive care units and other wards. J Antimicrob Chemother 1996, 37:809–813.
7. Patzer J, Dzierzanowska D: The resistance patterns and serotypes of Pseudomonas aeruginosa strains isolated from children. J Antimicrob Chemother 1999, 28:869–875.
8. Jamasbi RJ, Proudfoot EM: Phenotypic and genotypic characteristics of clinical isolates of Pseudomonas aeruginosa: rate of occurrence and distribution of different serotypes, antimicrobial susceptibility profiles, and molecular typing. Science 2008, 30:155–161.
9. Lu Q, Rouby JJ, Laterre PF, Eggimann P, Dugard A, Giamarellos-Bourboulis EJ, Mercier E, Garbino J, Lucu CE, Chastre J, Georges-Czyzkyvz V, Rudolf MP, Galvani V, Lazar H, Koch H, Perez A, Kramer SD, Tamam M: Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia. J Antimicrob Chemother 2011, 66:1110–1116.
10. American Thoracic Society, Infectious Diseases Society of America: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388–416.
11. Chastre J, Fagon JY: Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002, 165:867–903.
12. Rouby JJ, Martin De Lassale E, Poete P, Nicolas MH, Bodin L, Jalifer V, Le Charpentier Y, Grosset J, Vias P: Nosocomial bronchopneumonia in the critically ill. Histologic and bacteriologic aspects. Am Rev Respir Dis 1992, 146:1059–1066.
13. Pugin J, Auckenthaler R, Mil N, Janssens JP, Lewy PD, Suter PM: Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoalveolar "blind" bronchoalveolar lavage fluid. Am Rev Respir Dis 1991, 143:1211–1219.
14. Kraus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818–829.
15. Mertens I, Floersch A, Dufour P, Grangeon G, Janssens JP, Auckenthaler R: Ventilator-associated pneumonia due to Pseudomonas aeruginosa in a mechanically ventilated, critically ill patient. J Antimicrob Chemother 2001, 47:491–497.
16. Fontesca AP, Correia P, Sousa JC, Tenreiro R: Association patterns of Pseudomonas aeruginosa clinical isolates as revealed by virulence traits, antibiotic resistance, serotype and genotype. FEMS Infect Microbiol 2007, 51:505–516.
17. Nadjivi KC, Kocic B, Tiodorovic B, Brankovic S, Antic SM: Comparative distribution of resistance patterns and nonbronchoscopic "blind" bronchoalveolar lavage fluid. J Antimicrob Chemother 2009, 664:1129–1136.
18. Martis N, Mani J, Orsi GB, Gomis R, Foresti E, Visca P: Epidemiological characterization of human and environmental Pseudomonas aeruginosa strains: use of plasmid pattern analysis in addition to other typing methods. Ann J Infect Dis 1994, 653–664.
19. Vachey A, Scheffel JM, Husson MO, Izard D, Ross P, Monteil H: Tricentric study of the sensitivity of Pseudomonas aeruginosa serotyping to beta-lactams and aminoglycosides. Pathol Biol (Paris) 1997, 45:357–362.
20. Falcoau M, Mehta Y, Kharuna P, Chaudhary K, Kulkarni V, Trehan N: Ventilator-associated pneumonia due to Pseudomonas aeruginosa in mechanically ventilated critically ill patients. J Antimicrob Chemother 2005, 56:75–81.
21. Marquet T, Birmat JF, Misset B, Schwébel C, Azoulay E, Adrie C, Vesin A, Jamar S, Zahar JR, Aloucibiche B, Souweine B, Darmon M, Dumenil AS, Goldgrain-Teledano D, Morviller B, Bedos JP: Pseudomonas aeruginosa ventilator-associated pneumonia: predictive factors of treatment failure. Am J Respir Crit Care Med 2011, 184:689–76.
22. Bonnet S, Koulent D, Dimopoulos G, Martin C, Kornos A, Krueger WA, Spina G, Armaganidis A, Rello J: Prevalence, risk factors, and mortality for ventilator-associated pneumonia in middle-aged, old, and very old critically ill patients. Crit Care Med 2013, 41:624. Epub ahead of print.
23. Augustin DK, Song Y, Baek MS, Sawa Y, Singh G, Taylor B, Rubio-Mills A, Flanagan JL, Werner-Kronish JP, Lynch SV: Presence or absence of
lipopolysaccharide O antigens affects type III secretion by Pseudomonas aeruginosa. J Bacteriol 2007, 189:2203–2209.

35. Finck-Barbancon V, Goranson J, Zhu L, Sawa T, Wiener-Kronish JP, Fleisz SM, Wu C, Mende-Mueller L, Frank DW: ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury. Mol Microbiol 1997, 26:547–557.

36. Kurahashi K, Kajikawa O, Sawa T, Ohara M, Gropper MA, Frank DW, Martin TR, Wiener-Kronish JP: Pathogenesis of septic shock in Pseudomonas aeruginosa pneumonia. J Clin Invest 1999, 104:743–750.

37. Nicas TI, Igleswki BH: Contribution of exoenzyme S to the virulence of Pseudomonas aeruginosa. Antimicrob Chemother 1985, 36:40–48.

38. El Solh AA, Akinnusi ME, Wiener-Kronish JP, Lynch SV, Pineda LA, Szarpa K: Persistent infection with Pseudomonas aeruginosa in ventilator-associated pneumonia. Am J Respir Crit Care Med 2008, 178:513–519.

39. Hauser AR, Cobb E, Bodi M, Mariscal D, Valles J, Engel JN, Rello J: Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit Care Med 2002, 30:521–528.

40. Lisboa T, Waterer G, Rello J: We should be measuring genomic bacterial load and virulence factors. Crit Care Med 2010, 38:5656–5662.